Overall, we evaluated the potential of the ICG-HSA complex as a valuable fluorescence agent to improve FGS outcomes for glioblastoma patients by providing accurate resection of tumor margins via SPARC targeting of the tumor. This evidence concerns the gene ALB and glioblastoma.